INVA Q2 2024 Earnings — Innoviva, Inc. Revenue & Financial Results | Market Cap Arena

INVAInnoviva, Inc.

$1B

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$103M+27.6% YoY

Gross Profit

$85M82.2% margin

Operating Income

$55M52.9% margin

Net Income

-$35M-33.6% margin

EPS (Diluted)

$-0.55

QoQ Revenue Growth

+33.4%

Cash Flow

Operating Cash Flow

$44M

Free Cash Flow

$44M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$1.2B

Total Liabilities

$559M

Stockholders' Equity

$666M

Cash & Equivalents

$217M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$103M	$81M	+27.6%
Gross Profit	$85M	$57M	+49.0%
Operating Income	$55M	$18M	+195.7%
Net Income	-$35M	$1M	-2809.8%

Revenue Segments

Royalty

$64M64%

Product

$22M22%

License Revenue

$15M15%